Relieves osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis. ANDA 216275, held by Ingenus Pharms LLC. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 216275 (Diclofenac Sodium), held by Ingenus Pharms LLC, was first approved by FDA on Sep 23, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ). Diclofenac sodium extended-release tablets are indicated: for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 23, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium100MG · tablet, extended release;oral | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 23, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters